Physician profile
Eric Douglas Frusha
NPI 1174917652
$9,058.53
in general payments reported to CMS, 2019-2025
49 companies · $1,715 in 2025
The $1,715 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $387 · 2020: $390 · 2021: $985 · 2022: $2,177 · 2023: $1,950 · 2024: $1,454 · 2025: $1,715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,118.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,839.78 | 2020-2025 | |
| Glaxosmithkline, LLC. | $890.37 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $731.19 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $584.84 | 2021-2025 | Jardiance, Synjardy, Trijardy Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $535.17 | 2019-2025 | Trintellix |
| Novo Nordisk INC | $453.44 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $408.65 | 2022-2025 | Freestyle Libre 3, Freestyle Libre |
| Janssen Pharmaceuticals, INC | $312.54 | 2019-2025 | Spravato |
| Pfizer INC. | $276.62 | 2021-2025 | |
| Amgen INC. | $271.96 | 2022-2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $204.93 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $194.04 | 2021-2025 | Belsomra, Steglatro, Gardasil 9 |
| Amarin Pharma, INC. | $193.00 | 2020-2022 | |
| Axsome Therapeutics, INC. | $191.80 | 2023-2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $176.75 | 2019-2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Frusha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.